摘要
目的观察替雷利珠单抗联合DP化疗方案治疗晚期肺癌的疗效及对免疫功能的影响。方法选取2020年1月-2021年9月我院接诊的60例晚期肺癌患者为研究对象,采用随机数字表法分为对照组和观察组,各30例。对照组应用DP化疗方案治疗,观察组在对照组基础上联合替雷利珠单抗治疗,比较两组近期疗效、免疫功能指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))、血清肿瘤标志物[癌胚抗原(CEA)、糖抗原125(CA125)]、毒副反应、生存期。结果观察组客观缓解率、疾病控制率均高于对照组(P<0.05);两组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均高于治疗前,且观察组高于对照组(P<0.05);两组治疗后CEA、CA125水平低于治疗前,且观察组低于对照组(P<0.05);观察组白细胞减少、恶心呕吐、脱发、骨髓抑制发生率与对照组比较,差异无统计学意义(P>0.05);随访1年,观察组平均生存期大于对照组(P<0.05)。结论替雷利珠单抗联合DP化疗方案可一定程度提高晚期肺癌患者的疾病控制率和客观缓解率,改善免疫功能,降低肿瘤标志物水平,延长患者生存期,且不会增加毒副反应,具有应用安全性、有效性。
Objective To observe the curative effect and influence on immune function of terelizumab combined with DP chemotherapy in the treatment of advanced lung cancer.Methods A total of 60 patients with advanced lung cancer who were admitted to our hospital from January 2020 to September 2021 were selected as the research objects.They were divided into control group and observation group by random number table method,with 30 patients in each group.The control group was treated with DP chemotherapy regimen,and the observation group was treated with tirelizumab on the basis of the control group.The short-term efficacy,immune function indexes(CD3^(+),CD4^(+),CD4^(+)/CD8^(+)),serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)],toxic and side effects,and survival time were compared between the two groups.Results The objective remission rate and disease control rate of the observation group were higher than those of the control group(P<0.05).After treatment,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were higher than those before treatment,and those in the observation group were higher than the control group(P<0.05).After treatment,the levels of CEA and CA125 in the two groups were lower than those before treatment,and those in the observation group were lower than the control group(P<0.05).There was no significant difference in the incidence of leukopenia,nausea and vomiting,alopecia and bone marrow suppression between the observation group and the control group(P>0.05).After 1 year of follow-up,the average survival time of the observation group was longer than that of the control group(P<0.05).Conclusion Tenrealizumab combined with DP chemotherapy can improve the disease control rate and objective remission rate of patients with advanced lung cancer to a certain extent,improve immune function,reduce the level of tumor markers,prolong the survival time of patients,and will not increase toxic and side effects,with application safety and effectiveness.
作者
程家松
CHENG Jia-song(Department of Oncology,Poyang Lake Hospital,Poyang 333100,Jiangxi,China)
出处
《医学信息》
2023年第22期136-139,共4页
Journal of Medical Information
关键词
替雷利珠单抗
DP化疗
晚期肺癌
免疫功能
Tireilizumab
DP chemotherapy
Advanced lung cancer
Immune function
